Introduction {#s1}
============

Cancer is an outcome of unregulated expression of genes involved in development, cell growth, and differentiation. Many studies have shown that cancer is not only related to environmental factors, but also to individuals' genetic susceptibility (predisposition). Recently, a new mechanism of microRNA (miRNA)-mediated transcriptional regulation was elucidated [@pone.0079584-Ambros1]. MiRNAs are a class of single-stranded short (21∼25 nt) RNAs, which are evolutionarily well conserved but are non--protein-coding. These RNAs regulate a broad range of biologic and pathologic process, including apoptosis, proliferation, differentiation, angiogenesis, and immune response, which are known to play critical roles in carcinogenesis [@pone.0079584-Ambros1]--[@pone.0079584-Ruan1]. MiRNAs bind to the 3′-untranslated region of the target mRNAs, leading to their degradation or translational suppression, thereby regulating the expression of target genes at the post-transcriptional level [@pone.0079584-Bartel1]. Estimates suggest that a single miRNA can target hundreds of mRNAs, and approximately 50% miRNA genes are located in cancer-related chromosomal regions [@pone.0079584-Garzon1]--[@pone.0079584-Lu1]. Studies have shown that mature miRNAs regulate the expression of roughly 10--30% of all human genes [@pone.0079584-Berezikov1]. Moreover, recent studies have suggested that miRNAs may participate in the carcinogenesis, progression (proliferation, migration, and invasion), and prognosis of multiple human malignancies by regulating the expression of tumor suppressor genes or proto-oncogenes [@pone.0079584-Cho1]--[@pone.0079584-Garzon2].

Single nucleotide polymorphisms (SNPs) are the most common type of variation in the human genome, affecting sequence coding and splicing, which can influence the population diversity, disease susceptibility, and individual response to medicine [@pone.0079584-Shastry1]. SNPs can alter miRNA expression and/or maturation to affect function in three ways: through the transcription of the primary transcript, through pri-miRNA and pre-miRNA processing, and by affecting miRNA--mRNA interactions [@pone.0079584-Ryan1].

Many epidemiological studies have demonstrated the association of SNPs in miRNAs with the development and progression of cancer [@pone.0079584-Ryan1], [@pone.0079584-Mittal1]. MiR-146a rs2910164, miR-196a2 rs11614913, miR-499 rs3746444, miR-149 rs2292832, and miR-27a rs895919 are well-established miRNA polymorphisms [@pone.0079584-Akkiz1]--[@pone.0079584-Catucci1] that have been reported to be associated with cancer risk [@pone.0079584-Ryan1]. However, conclusions of these studies remain inconsistent due to heterogeneity of the cancer subtype, limited sample size, and differences in the ethnicity of patients. To better assess the association of miR-146a rs2910164, miR-196a2 rs11614913, miR-499 rs3746444, miR-149 rs2292832, and miR-27a rs895919 in the miRNA genes with cancer risk, we conducted a meta-analysis of all eligible published case-control studies and evaluated the effect of the five SNPs on overall cancer risk. The effects of tumor type, ethnicity, source of controls, and sample size were also evaluated.

Materials and Methods {#s2}
=====================

Publication Search {#s2a}
------------------

To identify all potentially eligible studies on miRNA polymorphisms and cancer risk, we carried out a systematic search on PubMed, Web of Science, Science Direct, and Embase, covering all papers published up to June 30, 2013, by using the search terms: "microRNA 146a/196a2/499/149/27a", "mir-146a/196a2/499/27a", "polymorphism", and "cancer". References of the retrieved articles and review articles were also screened. Eligible studies had to meet all of the following criteria: (a) full-text study, (b) evaluation of the association between miRNA polymorphisms and cancer risk, (c) unrelated case-control design, and (d) sufficient data for estimating the odds ratio (OR) with 95% confidence interval (CI) and a *P*-value. Studies containing two or more case-control groups were considered as two or more independent studies.

Data Extraction {#s2b}
---------------

Two investigators independently reviewed and extracted information from all publications that met the inclusion criteria. In the case of a conflict, an agreement was reached by discussion between the two reviewers. The following information was sought from each publication: first author's surname, year of publication, country of origin, ethnicity, cancer type, genotyping method, source of control groups, numbers of cases and controls for each genotype.

Statistical Analysis {#s2c}
--------------------

We first assessed the departure of frequencies of miRNA polymorphisms from expectation under Hardy-Weinberg equilibrium (HWE) for each study by using the goodness-of-fit test (chi-square or Fisher exact test) in controls. Crude OR corresponding to 95% CI was used to assess the strength of the association between miRNA polymorphisms and cancer risk according to the methods published by Woolf *et al* [@pone.0079584-Woolf1]. The statistical significance of the pooled OR was determined by the Z-test, and a *P*-value of \<0.05 was considered statistically significant. For *miR-146a* G/C, we investigated the association between genetic variants and cancer risk in allelic contrast (C vs. G), homozygote comparisons (CC vs. GG), heterozygote comparisons (GC vs. GG), dominant model (CC+GC vs. GG) and recessive models (CC vs. GC+GG), respectively. The same method was applied to analyze other polymorphisms. Subgroup analyses were also conducted by ethnicity (Caucasian and Asian), cancer types (if one cancer type contained only one individual study, it was combined into other cancer subgroups), source of control (population-based and hospital-based), and sample size (small sample: the total number of controls and cases less than 1000; large sample: the total number of controls and cases not less than 1000).

Statistical heterogeneity between studies was checked by Cocharan's chi-square based Q-test [@pone.0079584-Cochran1]. However, as the Q test was insensitive in cases where studies were small or few, *I^2^* values were also calculated, which represent the percentage of total variation across studies and provide a result of heterogeneity rather than chance. If the *P*-value for heterogeneity was \<0.05, or if *I^2^* was ≥50%, indicating substantial heterogeneity among studies, then a random-effect model using the DerSimonian and Laird method [@pone.0079584-DerSimonian1], which yielded wider CIs, was chosen to calculate the pooled OR; otherwise, a fixed-effect model using the Mantel-Haenszel method [@pone.0079584-Mantel1] was used. One-way sensitivity analyses were performed to assess the stability of the meta-analysis results [@pone.0079584-A1]. Potential publication bias was estimated using Egger's linear regression test by visual inspection of the Funnel plot. A *P* value \<0.05 was used as an indication of potential publication bias [@pone.0079584-Egger1]. All statistical analyses were carried out with the STATA software package version 10.0 (Stata Corporation, College Station, TX).

Results {#s3}
=======

Study Identification {#s3a}
--------------------

In total, 66 published articles [@pone.0079584-Mittal1]--[@pone.0079584-Okubo1], [@pone.0079584-Horikawa1]--[@pone.0079584-Catucci1], [@pone.0079584-Orsos1]--[@pone.0079584-Wei2] ([Table 1](#pone-0079584-t001){ref-type="table"}), with 127 comparisons, were identified through literature search with different combinations of key terms and were selected based on the inclusion criteria ([Figure 1](#pone-0079584-g001){ref-type="fig"}). During data extraction, 85 out of 151 articles were excluded, including 34 articles on meta-analysis, 35 articles that were not about cancer, 12 articles that were concerned with cancer prognosis, 1 article that provided incomplete polymorphism distribution data, and 3 articles that lacked full text. Two articles [@pone.0079584-Song1], [@pone.0079584-Christensen1] that did not provide the distribution of all three genotypes in detail, but presented genotypes as CC+GC and GG were still kept in our analysis. In two studies [@pone.0079584-Catucci2], [@pone.0079584-Jazdzewski1], genotype frequencies were presented separately according to the country of origin of the study subjects, and thus each of these studies was treated as a separate study. In addition, Zhang *et al.* [@pone.0079584-Zhang1] investigated two types of cancers in one study. Each type of cancer in this article was considered separately for meta-analysis.

![Flow chart of the study selection process.](pone.0079584.g001){#pone-0079584-g001}
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###### Main characteristics of studies included in the meta-analysis.

![](pone.0079584.t001){#pone-0079584-t001-1}

          Author                  Ref                Year        Country        Ethnicity            Cancer type             Design   Genotyping methods   Number of cases/controls   Genotypes distribution of cases/controls   HWE (P)             
  ---- ------------- ------------------------------ ------ ------------------- ----------- -------------------------------- -------- -------------------- -------------------------- ------------------------------------------ --------- ---------- ------
  1      Horikawa      [@pone.0079584-Horikawa1]     2008          USA          Caucasian         Renal Cell Cancer            PB        SNPlex assay              261/235                            144/126                    103/94     14/15     0.65
  2     Jazdzewski    [@pone.0079584-Jazdzewski1]    2008        Finland        Caucasian                PTC                   PB        SNuPE Assay               206/274                             99/150                    104/105     3/19     0.91
  3     Jazdzewski    [@pone.0079584-Jazdzewski1]    2008        Poland         Caucasian                PTC                   PB        SNuPE Assay               201/475                            115/286                    82/163      4/26     0.66
  4     Jazdzewski    [@pone.0079584-Jazdzewski1]    2008          USA          Caucasian                PTC                   PB        SNuPE Assay               201/152                             91/90                     101/52      9/10     0.51
  5         Xu            [@pone.0079584-Xu3]        2008         China           Asian              Liver Cancer              HB          PCR-RFLP                479/504                             80/58                     241/249   158/197    0.12
  6        Yang          [@pone.0079584-Yang2]       2008          USA          Caucasian           Bladder Cancer             PB        SNPlex assay              691/674                            414/385                    242/258    35/31     0.14
  7       Hoffman       [@pone.0079584-Hoffman1]     2009          USA          Caucasian           Breast Cancer            PB/HB        massARRAY                439/478                            234/273                    176/178    29/27     0.77
  8         Hu            [@pone.0079584-Hu1]        2009         China           Asian             Breast Cancer              PB          PCR-RFLP               1009/1093                           165/180                    515/551   329/362    0.22
  9        Tian          [@pone.0079584-Tian1]       2009         China           Asian              Lung Cancer               PB          PCR-RFLP               1058/1035                           360/364                    510/502   188/169    0.85
  10      Catucci       [@pone.0079584-Catucci2]     2010         Italy         Caucasian           Breast Cancer              PB         Sequencing               754/1243                           409/650                    286/520    59/73     0.02
  11      Catucci       [@pone.0079584-Catucci2]     2010        Germany        Caucasian           Breast Cancer              PB         Sequencing               805/904                            451/536                    304/318    50/50     0.75
  12        Guo           [@pone.0079584-Guo1]       2010         China           Asian                  ESCC                  PB          SNaPshot                444/468                            234/206                    190/220    20/42     0.12
  13        Liu           [@pone.0079584-Liu1]       2010          USA          Caucasian               SCCHN                  HB          PCR-RFLP               1109/1130                           630/655                    411/405    68/70     0.49
  14       Okubo         [@pone.0079584-Okubo1]      2010         Japan           Asian             Gastric Cancer             HB          PCR-RFLP                552/697                             73/121                    243/322   236/254    0.28
  15     Pastrello     [@pone.0079584-Pastrello1]    2010         Italy         Caucasian   Mix(breast and ovarian cancer)     PB         Sequencing               101/155                             60/90                      36/59      5/6      0.33
  16    Srivastava    [@pone.0079584-Srivastava1]    2010         India           Asian           Gallbladder Cancer           PB          PCR-RFLP                230/224                            129/138                     90/81      11/5     0.08
  17        Xu            [@pone.0079584-Xu2]        2010         China           Asian            Prostate Cancer             HB          PCR-RFLP                251/280                             68/54                     135/150    48/76     0.19
  18       Zeng          [@pone.0079584-Zeng1]       2010         China           Asian             Gastric Cancer             HB          PCR-RFLP                304/304                             62/53                     153/132    89/119    0.12
  19       Akkiz         [@pone.0079584-Akkiz3]      2011        Turkey         Caucasian            Liver Cancer              HB          PCR-RFLP                222/222                            137/144                     75/67     10/11     0.38
  20      Garcia        [@pone.0079584-Garcia1]      2011        French         Caucasian           Breast Cancer              PB           TaqMan                 1130/596                           676/352                    388/220    66/24     0.15
  21      George        [@pone.0079584-George1]      2011         India           Asian            Prostate Cancer             PB          PCR-RFLP                159/230                              4/7                      79/107     76/116    0.00
  22      Hishida       [@pone.0079584-Hishida1]     2011         Japan           Asian             Gastric Cancer             HB          PCR-CTPP                583/1637                            82/229                    271/775   230/633    0.74
  23      Mittal        [@pone.0079584-Mittal1]      2011         India           Asian             Bladder Cancer             PB          PCR-RFLP                212/250                            127/135                    79/108      6/7      0.01
  24    Permuth-Wey   [@pone.0079584-PermuthWey1]    2011          USA          Caucasian               Glioma                 PB         GoldenGate               593/614                            345/375                    198/214    50/25     0.42
  25       Vinci         [@pone.0079584-Vinci2]      2011         Italy         Caucasian               NSCLC                  NR            HRMA                  101/129                             44/73                      48/45      9/11     0.29
  26        Yue           [@pone.0079584-Yue1]       2011         China           Asian            Cervical Cancer             HB          PCR-RFLP                447/443                             118/87                    224/206   105/150    0.29
  27       Zhang         [@pone.0079584-Zhang3]      2011         China           Asian              Liver Cancer              HB         PIRA--PCR                925/1593                           156/291                    450/725   319/577    0.02
  28       Zhou          [@pone.0079584-Zhou1]       2011         China           Asian                  CSCC                  HB          PCR-RFLP                226/309                             43/34                     113/159    70/116    0.06
  29     Alshatwi         [@pone.0079584-Ma2]        2012         Saudi           Asian             Breast Cancer              PB           TaqMan                 100/100                              2/3                       50/46     48/51     0.05
  30        Chu          [@pone.0079584-Zhou3]       2012         China           Asian              Oral Cancer               HB          PCR-RFLP                470/425                             54/54                     242/196   174/175    0.94
  31      Hezova         [@pone.0079584-Chen1]       2012         Czech         Caucasian         Colorectal Cancer            HB           TaqMan                 197/212                            115/124                     70/79     12//9     0.41
  32        Kim          [@pone.0079584-Zhang1]      2012         Korea           Asian              Liver Cancer              PB          PCR-RFLP                286/201                             27/24                     159/103    100/74    0.19
  33       Lung          [@pone.0079584-Lung1]       2012         China           Asian        Nasopharyngeal Carcinoma        PB          Tm-shift                229/3631                            24/497                    88/1721   117/1413   0.46
  34     Mihalache       [@pone.0079584-Zhang2]      2012   Italy and Germany   Caucasian         Cholangiocarcinoma           HB           TaqMan                 182/350                            118/211                    53/122     11/17     0.91
  35        Min          [@pone.0079584-Vinci1]      2012         Korea           Asian           Colorectal Cancer            HB          PCR-RFLP                446/502                             62/69                     233/245   151/188    0.44
  36       Wang          [@pone.0079584-Song1]       2012         China           Asian             Bladder Cancer             HB           TaqMan                1017/1179                           369/340                    456/571   192/268    0.34
  37       Xiang          [@pone.0079584-Ma1]        2012         China           Asian              Liver Cancer              HB          PCR-RFLP                100/200                             27/45                     45/100     28/55     0.97
  38       Zhou           [@pone.0079584-Wei1]       2012         China           Asian              Liver Cancer              PB          PCR-RFLP                186/483                             33/71                     86/254     67/158    0.06
  39       Zhou        [@pone.0079584-Yamashita1]    2012         China           Asian             Gastric Cancer             HB           TaqMan                1686/1895                           578/551                    822/951   286/393    0.64
  40        Ma          [@pone.0079584-Mantel1]      2013         China           Asian                  TNBC                  HB         massARRAY                192/191                             35/34                      94/93     63/64     0.98
  41        Ma           [@pone.0079584-Egger1]      2013         China           Asian           Colorectal Cancer            HB           TaqMan                1147/1203                           444/397                    534/614   169/192    0.08
  42       ORSÓS         [@pone.0079584-Woolf1]      2013        Hungary        Caucasian               SCCHN                  PB          PCR-RFLP                468/468                            284/323                    168/136     16/9     0.22
  43       Song          [@pone.0079584-Orsos1]      2013          USA          Caucasian                OSCC                  HB          PCR-RFLP                325/335                            184/203                      --         --       --
  44       Vinci           [@pone.0079584-A1]        2013         Italy         Caucasian         Colorectal Cancer            NR            HRMA                  160/178                             86/100                     57/65     17/13     0.59
  45        Wei       [@pone.0079584-DerSimonian1]   2013         China           Asian                  PTC                   PB         massARRAY                753/760                            136/138                    323/345   294/277    0.09
  46        Wei           [@pone.0079584-Wei2]       2013         China           Asian                  ESCC                  HB         massARRAY                368/370                             67/67                     184/181   117/122    0.99
  47     Yamashita      [@pone.0079584-Cochran1]     2013         Japan           Asian           Malignant melanoma           NR          PCR-RFLP                 50/107                              0/3                       35/53     15/51     0.01
                                                                                                                                                                                              **miR-196a2 rs11614913**                               
                                                                                                                                                                                                       **CC**                    **CT**     **TT**   
  1      Horikawa      [@pone.0079584-Horikawa1]     2008          USA          Caucasian         Renal Cell cancer            PB        SNPlex assay              276/277                            105/101                    126/117    45/59     0.02
  2        Yang          [@pone.0079584-Yang2]       2008          USA          Caucasian           Bladder Cancer             PB        SNPlex assay              736/731                            255/257                    348/342   133/132    0.32
  3       Hoffman       [@pone.0079584-Hoffman1]     2009          USA          Caucasian           Breast Cancer            PB/HB        massARRAY                426/466                            181/166                    209/229    36/71     0.58
  4         Hu            [@pone.0079584-Hu1]        2009         China           Asian             Breast Cancer              PB          PCR-RFLP               1009/1093                           239/218                    483/517   287/358    0.21
  5        Tian          [@pone.0079584-Tian1]       2009         China           Asian              Lung Cancer               PB          PCR-RFLP               1058/1035                           253/209                    512/519   293/307    0.70
  6       Catucci       [@pone.0079584-Catucci2]     2010         Italy         Caucasian           Breast Cancer              PB           TaqMan                 751/1243                           334/532                    330/550    87/161    0.32
  7       Catucci       [@pone.0079584-Catucci2]     2010        Germany        Caucasian           Breast Cancer              PB           TaqMan                1101/1496                           432/584                    512/696   157/216    0.71
  8     Christensen   [@pone.0079584-Christensen1]   2010          USA          Caucasian               SCCHN                  PB           Taqman                 484/555                            182/188                      --         --       --
  9         Dou           [@pone.0079584-Dou1]       2010         China           Asian                 Glioma                 HB          PCR-LDR                 643/656                            111/143                    343/305   189/208    0.12
  10        Kim           [@pone.0079584-Kim2]       2010         Korea           Asian              Lung Cancer               HB          PCR-FRET                654/640                            187/155                    305/300   162/185    0.13
  11        Li            [@pone.0079584-Li1]        2010         China           Asian              Liver Cancer              HB          PCR-RFLP                310/222                             78/42                     150/102    82/78     0.40
  12        Liu           [@pone.0079584-Liu1]       2010          USA          Caucasian               SCCHN                  HB          PCR-RFLP               1109/1130                           350/383                    565/545   194/202    0.74
  13       Okubo         [@pone.0079584-Okubo1]      2010         Japan           Asian             Gastric Cancer             HB          PCR-RFLP                552/697                            105/124                    281/350   166/223    0.51
  14       Peng          [@pone.0079584-Peng1]       2010         China           Asian             Gastric Cancer             HB          PCR-RFLP                213/213                             76/161                    94/107     43/50     0.94
  15        Qi            [@pone.0079584-Qi1]        2010         China           Asian              Liver Cancer              HB          PCR-LDR                 361/590                             82/125                    179/304   100/161    0.40
  16    Srivastava    [@pone.0079584-Srivastava1]    2010         India           Asian           Gallbladder Cancer           PB          PCR-RFLP                230/230                            119/136                     95/75     16/19     0.07
  17       Wang          [@pone.0079584-Wang2]       2010         China           Asian                  ESCC                  HB          SNaPshot                458/489                            148/128                    262/250    48/111    0.60
  18       Akkiz         [@pone.0079584-Akkiz3]      2011        Turkey         Caucasian            Liver Cancer              HB          PCR-RFLP                185/185                             77/58                      86/87     22/40     0.49
  19      George        [@pone.0079584-George1]      2011         India           Asian            Prostate Cancer             PB          PCR-RFLP                159/230                             55/106                    101/114     3/10     0.00
  20       Hong          [@pone.0079584-Hong1]       2011         Korea           Asian              Lung Cancer               HB           Taqman                 406/428                             86/96                     224/198    96/134    0.16
  21     Jedlinski     [@pone.0079584-Jedlinski1]    2011       Australia       Caucasian           Breast Cancer              PB          PCR-RFLP                187/171                             68/58                      86/82     33/31     0.83
  22      Mittal        [@pone.0079584-Mittal1]      2011         India           Asian             Bladder Cancer             PB          PCR-RFLP                212/250                             76/109                    131/127     5/14     0.00
  23       Vinci         [@pone.0079584-Vinci2]      2011         Italy         Caucasian               NSCLC                  NR            HRMA                  101/129                             35/58                      54/61     12/10     0.27
  24       Zhan          [@pone.0079584-Zhan1]       2011         China           Asian           Colorectal Cancer            HB          PCR-RFLP                252/543                             68/113                    128/267    56/163    0.85
  25       Zhang         [@pone.0079584-Zhang3]      2011         China           Asian              Liver Cancer              HB         PIRA--PCR                934/1622                           208/328                    449/817   277/477    0.52
  26       Zhou          [@pone.0079584-Zhou1]       2011         China           Asian                  CSCC                  HB          PCR-RFLP                226/309                             46/58                     123/169    57/82     0.08
  27     Alshatwi         [@pone.0079584-Ma2]        2012         Saudi           Asian             Breast Cancer              PB           TaqMan                 100/100                             35/46                      63/50      2/4      0.03
  28       Chen        [@pone.0079584-Mihalache1]    2012         China           Asian                  CRC                   HB          PCR--LDR                126/407                             27/94                     64/206     35/107    0.79
  29        Chu          [@pone.0079584-Zhou3]       2012         China           Asian              Oral Cancer               HB          PCR-PFLP                470/425                             57/87                     277/206   136/132    0.69
  30      Hezova         [@pone.0079584-Chen1]       2012         Czech         Caucasian         Colorectal Cancer            HB           TaqMan                 197/212                             82/87                     89/103     26/22     0.29
  31        Kim          [@pone.0079584-Zhang1]      2012         Korea           Asian              Liver Cancer              PB          PCR-RFLP                286/201                             58/45                     154/107    74/49     0.36
  32     Linhares        [@pone.0079584-Zhou4]       2012        Brazil         Caucasian           Breast Cancer              HB           TaqMan                 325/274                             83/94                     148/114    94/66     0.00
  33        Min          [@pone.0079584-Vinci1]      2012         Korea           Asian           Colorectal Cancer            HB          PCR-RFLP                446/502                            120/100                    201/254   125/148    0.63
  34       Zhang         [@pone.0079584-Wang1]       2012         China           Asian             Breast Cancer              PB          PCR-RFLP                248/243                              1/17                      89/93    148/133    0.89
  35        Zhu           [@pone.0079584-Kim1]       2012         China           Asian           Colorectal Cancer            HB           TaqMan                 573/588                            140/121                    303/295   130/172    0.79
  36       Song          [@pone.0079584-Orsos1]      2013          USA          Caucasian                OSCC                  HB          PCR-RFLP                325/335                             95/96                       --         --       --
  37       Vinci           [@pone.0079584-A1]        2013         Italy         Caucasian                CRC                   NR            HRMA                  160/178                             62/83                      86/84     12/11     0.09
  38        Wei           [@pone.0079584-Wei2]       2013         China           Asian                  ESCC                  HB         massARRAY                367/370                             65/87                     196/170   106/113    0.14
                                                                                                                                                                                               **miR-499 rs3746444**                                 
                                                                                                                                                                                                       **TT**                    **TC**     **CC**   
  1         Hu            [@pone.0079584-Hu1]        2009         China           Asian             Breast Cancer              PB          PCR-RFLP               1093/1009                           707/816                    258/248    44/29     0.06
  2        Tian          [@pone.0079584-Tian1]       2009         China           Asian              Lung Cancer               PB          PCR-RFLP               1035/1058                           781/755                    253/254    24/26     0.40
  3       Catucci       [@pone.0079584-Catucci2]     2010         Italy         Caucasian           Breast Cancer              PB         Sequencing               1242/756                           414/704                    295/452    47/86     0.25
  4       Catucci       [@pone.0079584-Catucci2]     2010        Germany        Caucasian           Breast Cancer              PB         Sequencing               925/823                            536/601                    250/290    37/34     0.89
  5         Liu           [@pone.0079584-Liu1]       2010          USA          Caucasian               SCCHN                  HB          PCR-RFLP               1130/1109                           745/710                    309/366    55/54     0.44
  6        Okubo         [@pone.0079584-Okubo1]      2010         Japan           Asian             Gastric Cancer             HB          PCR-RFLP                697/552                            364/466                    151/198    37/33     0.05
  7     Srivastava    [@pone.0079584-Srivastava1]    2010         India           Asian           Gallbladder Cancer           PB          PCR-RFLP                230/230                            112/121                     97/94     21/15     0.57
  8        Akkiz         [@pone.0079584-Akkiz3]      2011        Turkey         Caucasian            Liver Cancer              HB          PCR-RFLP                222/222                             45/47                      87/93     90/82     0.04
  9       George        [@pone.0079584-George1]      2011         India           Asian            Prostate Cancer             PB          PCR-RFLP                230/159                             48/104                     98/92     13/34     0.07
  10      Mittal        [@pone.0079584-Mittal1]      2011         India           Asian             Bladder Cancer             PB          PCR-RFLP                250/212                             95/121                     92/94     25/35     0.02
  11       Vinci         [@pone.0079584-Vinci2]      2011         Italy         Caucasian            Lung Cancer               NR            HRMA                  129/101                             53/70                      41/48      7/11     0.50
  12       Zhou          [@pone.0079584-Zhou1]       2011         China           Asian                  CSCC                  HB          PCR-RFLP                309/226                            134/223                     84/71      8/15     0.00
  13     Alshatwi         [@pone.0079584-Ma2]        2012         Saudi           Asian             Breast Cancer              PB           TaqMan                 100/100                             30/45                      62/40      8/15     0.23
  14        Chu          [@pone.0079584-Zhou3]       2012         China           Asian              Oral Cancer               HB          PCR-PFLP                425/270                            339/356                    119/66      12/3     0.98
  15        Kim          [@pone.0079584-Zhang1]      2012         Korea           Asian              Liver Cancer              PB          PCR-RFLP                201/286                            200/120                     81/74      5/7      0.28
  16        Min          [@pone.0079584-Vinci1]      2012         Korea           Asian           Colorectal Cancer            HB          PCR-RFLP                502/446                            292/334                    142/154    12/14     0.45
  17       Xiang          [@pone.0079584-Ma1]        2012         China           Asian              Liver Cancer              HB          PCR-RFLP                200/100                             36/106                     40/71     24/23     0.04
  18       Zhou           [@pone.0079584-Wei1]       2012         China           Asian              Liver Cancer              PB          PCR-RFLP                483/186                            141/371                    41/100      4/12     0.10
  19       Song          [@pone.0079584-Orsos1]      2013          USA          Caucasian                OSCC                  HB          PCR-RFLP                325/335                            184/214                      --         --       --
  20       Vinci           [@pone.0079584-A1]        2013         Italy         Caucasian                CRC                   NR            HRMA                  178/160                             93/105                     32/56     35/17     0.03
  21        Wei           [@pone.0079584-Wei2]       2013         China           Asian                  ESCC                  HB         massARRAY                358/376                            291/289                     60/76      7/11     0.14
                                                                                                                                                                                               **miR-149 rs2292832**                                 
                                                                                                                                                                                                       **CC**                    **CT**     **TT**   
  1         Hu            [@pone.0079584-Hu1]        2009         China           Asian             Breast Cancer              PB          PCR-RFLP               1009/1093                           450/482                    460/503    99/108    0.16
  2        Tian          [@pone.0079584-Tian1]       2009         China           Asian              Lung Cancer               PB          PCR-RFLP               1058/1035                           123/112                    472/453   463/470    0.86
  3         Liu           [@pone.0079584-Liu1]       2010          USA          Caucasian               SCCHN                  HB          PCR-RFLP               1109/1130                           580/586                    441/445    88/99     0.27
  4        Vinci         [@pone.0079584-Vinci2]      2011         Italy         Caucasian               NSCLC                  NR            HRMA                  101/129                             44/65                      41/53     16/11     0.97
  5         Chu          [@pone.0079584-Zhou3]       2012         China           Asian              Oral Cancer               HB          PCR-PFLP                470/425                             37/26                      88/84    345/315    0.00
  6         Kim          [@pone.0079584-Zhang1]      2012         Korea           Asian              Liver Cancer              PB          PCR-RFLP                286/201                             24/21                     113/97     149/83    0.34
  7         Min          [@pone.0079584-Vinci1]      2012         Korea           Asian           Colorectal Cancer            HB          PCR-RFLP                446/502                             48/51                     177/219   221/232    0.95
  8        Zhang       [@pone.0079584-Alshatwi1]     2012         China           Asian           Colorectal Cancer            PB          PCR-RFLP                443/435                             50/46                     190/202   203/187    0.43
  9        Zhang       [@pone.0079584-Alshatwi1]     2012         China           Asian             Gastric Cancer             PB          PCR-RFLP                274/269                             41/35                     101/120   132/114    0.70
  10       Zhang         [@pone.0079584-Wang1]       2012         China           Asian             Breast Cancer              PB          PCR-RFLP                245/229                             23/24                     102/113    120/92    0.21
  11       Song          [@pone.0079584-Orsos1]      2013          USA          Caucasian                OSCC                  HB          PCR-RFLP                325/335                            158/162                      --         --       --
  12       Vinci           [@pone.0079584-A1]        2013         Italy         Caucasian                CRC                   NR            HRMA                  160/178                             79/86                      58/75     23/17     0.91
                                                                                                                                                                                                **miR-27a rs895919**                                 
                                                                                                                                                                                                       **AA**                    **AG**     **GG**   
  1       Hoffman       [@pone.0079584-Hoffman1]     2009          USA            Mixed             Breast Cancer            PB/HB        massARRAY                434/477                            184/220                    200/211    50/46     0.65
  2         Sun           [@pone.0079584-Sun1]       2010         China           Asian             Gastric Cancer             HB          PCR-RFLP                304/304                            115/145                    135/119    54/40     0.05
  3        Yang          [@pone.0079584-Yang1]       2010        Germany        Caucasian           Breast Cancer              PB         Sequencing              1189/1416                           576/605                    486/660   127/151    0.14
  4       Catucci      [@pone.0079584-Linhares1]     2012         Italy         Caucasian           Breast Cancer              PB           TaqMan                1025/1593                           547/803                    388/633    90/157    0.05
  5       Hezova         [@pone.0079584-Chen1]       2012         Czech         Caucasian         Colorectal Cancer            HB           TaqMan                 197/212                             88/93                      86/94     23/25     0.29
  6         Shi           [@pone.0079584-Chu1]       2012         China           Asian           Renal Cell Cancer            HB           TaqMan                 594/600                            334/288                    213/262    47/50     0.37
  7        Zhang         [@pone.0079584-Wang1]       2012         China           Asian             Breast Cancer              PB          PCR-RFLP                245/243                             60/75                     144/109    41/59     0.12
  8        Zhou           [@pone.0079584-Zhu1]       2012         China           Asian             Gastric Cancer             HB         massARRAY                295/413                            166/214                    122/167     7/32     0.94
  9         Wei           [@pone.0079584-Wei2]       2013         China           Asian                  ESCC                  HB         massARRAY                379/377                            216/208                    143/139    20/30     0.14

HB: hospital based; PB: population based; Mixed: hospital and population based; NR: not reported; PTC: papillary thyroid carcinoma; ESCC: esophageal squamous cell carcinoma; SCCHN: squamous cell carcinoma of the head and neck; NSCLC: non-small cell lung cancer; CSCC: cervical cancer; TNBC: triple negative breast cancer; OSCC: oral squamous cell carcinoma; CRC: colorectal cancer; PCR-RFLP: polymerase chain reaction--restriction fragment length polymorphism; HRMA: high-resolution melting analysis; PIRA--PCR: primer-introduced restriction analysis-polymerase chain reaction; PCR-LDR: polymerase chain reaction-ligation detection reaction; PCR-FRET: polymerase chain reaction-fluorescence resonance energy transfer; Tm-shift: melting-temperature --shift allele-specific genotyping; HWE: Hardy-Weinberg equilibrium; *P*: p value.

Overall, 47, 38, 21, 12, and 9 studies were pooled for meta-analysis of the rs2910164, rs11614913, rs3746444, rs2292832, and rs895919, respectively. Among all the included articles, there were 11 articles on liver cancer and breast cancer each, 8 studies on gastric cancer and colorectal cancer each, 5 studies on squamous cell carcinoma of the head and neck (SCCHN), 4 studies on lung cancer, 3 studies on bladder cancer and esophageal squamous cell carcinoma (ESCC) each, 2 studies on prostate cancer, glioma cancer, renal cell cancer, papillary thyroid carcinoma (PTC) and cervical cancer each, and 1 study each on gallbladder cancer, malignant melanoma and breast/ovarian cancer. The ethnicity of subjects in 42 studies and 24 studies were Asian and Caucasian, respectively. The controls from 37 studies came from a hospital-based population, whereas 25 studies had population-based controls. One study included both population-based and hospital-based controls [@pone.0079584-Hoffman1], while three studies lacked the information of control source [@pone.0079584-Yamashita1], [@pone.0079584-Vinci1], [@pone.0079584-Vinci2]. To determine the SNPs, multiple genotyping methods were employed including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), TaqMan assay, SNPlex, SNuPE Assay, high-resolution melting analysis (HRMA), polymerase chain reaction-ligation detection reaction (PCR-LDR), direct sequencing, SNaPshot, Sequenom's MassARRAY, fluorescence labeled hybridization (PCR-FRET), polymerase chain reaction with confronting two-pair primers (PCR-CTTP), Illumina's GoldenGate, primer introduced restriction analysis- polymerase chain reaction (PIRA-PCR) and Tm-shift allele-specific genotyping. Genotypic distribution of most of the studied SNPs was in agreement with HWE (*P*\>0.05) in controls.

Quantitative Synthesis {#s3b}
----------------------

### miR-146a rs2910164 {#s3b1}

For miR-146a rs2910164 polymorphism, our study contained 47 comparisons with 22,055 cases and 29,138 controls. The frequency of the rs2910164 C allele had a significantly higher representation in the Asian population compared to the Caucasian population (Asian: 54.3%, 95% CI = 49.1--59.4%; Caucasian: 24.2%, 95% CI = 22.9--25.4%; *P*\<0.001).

The results of the meta-analysis on rs2910164 and cancer risk are shown in [Table 2](#pone-0079584-t002){ref-type="table"}. Overall, no significant association was found between rs2910164 and cancer risk under any genetic model when all the eligible studies were pooled into the meta-analysis. After exclusion of four studies [@pone.0079584-Mittal1], [@pone.0079584-Yamashita1], [@pone.0079584-Zhang3], [@pone.0079584-Catucci2], whose genotypic distributions in controls were not in agreement with HWE, the results did not significantly change.

10.1371/journal.pone.0079584.t002

###### Meta-analysis of miR-146a rs2910164 polymorphism with cancer risk.

![](pone.0079584.t002){#pone-0079584-t002-2}

  Variables               n[a](#nt103){ref-type="table-fn"}         C vs. G         CC vs. GG   GC vs. GG   CC+GC vs. GG      CC vs. GC+GG                                                                                                                                                                             
  ---------------------- ----------------------------------- --------------------- ----------- ----------- -------------- --------------------- --------- --------- ------ --------------------- --------- --------- ------ --------------------- --------- --------- ------ --------------------- --------- --------- ------
  **Total**                              47                   0.978(0.931--1.027)     0.375      \<0.001        63.6       0.952(0.851--1.065)    0.393    \<0.001   60.5   0.982(0.921--1.048)    0.588    \<0.001   45.9   0.983(0.919--1.051)    0.614    \<0.001   55.4   0.959(0.880--1.045)    0.339    \<0.001   58.9
  **Cancer type**                                                                                                                                                                                                                                                                                                      
  Bladder Cancer                          3                   0.838(0.762--0.921)     0.001       0.324         11.2       0.724(0.587--0.893)    0.003     0.241    29.7   0.789(0.689--0.904)    0.001     0.526    0.0    0.781(0.687--0.889)   \<0.001    0.290    19.3   0.836(0.693--1.010)    0.063     0.446    0.0
  Breast Cancer                           7                   1.032(0.966--1.102)     0.353       0.864         0.0        1.138(0.970--1.335)    0.112     0.818    0.0    0.999(0.907--1.099)    0.976     0.485    0.0    1.025(0.935--1.123)    0.601     0.682    0.0    1.073(0.944--1.219)    0.282     0.504    0.0
  Cervical Cancer                         2                   0.719(0.620--0.835)    \<0.001      0.796         0.0        0.503(0.370--0.684)   \<0.001    0.814    0.0    0.721(0.545--0.953)    0.022     0.254    23.1   0.632(0.485--0.823)    0.001     0.382    0.0    0.654(0.520--0.822)   \<0.001    0.359    0.0
  Colorectal Cancer                       4                   0.912(0.833--0.999)     0.047       0.324         13.6       0.873(0.716--1.064)    0.179     0.281    21.5   0.854(0.740--0.985)    0.030     0.376    3.4    0.859(0.750--0.984)    0.028     0.294    19.2   0.926(0.785--1.091)    0.357     0.393    0.0
  ESCC                                    2                   0.841(0.631--1.121)     0.237       0.047         74.6       0.648(0.288--1.457)    0.294     0.021    81.1   0.834(0.667--1.042)    0.109     0.235    29.2   0.815(0.585--1.134)    0.224     0.142    53.7   0.700(0.360--1.362)    0.294     0.033    77.9
  Gastric Cancer                          4                   0.953(0.782--1.162)     0.633      \<0.001        86.4       0.915(0.625--1.339)    0.648    \<0.001   84.1   0.907(0.806--1.020)    0.104     0.136    45.8   0.960(0.742--1.240)    0.753     0.011    73.1   0.919(0.700--1.206)    0.543    \<0.001   83.5
  Lung Cancer                             2                   1.079(0.959--1.214)     0.205       0.209         36.7       1.139(0.891--1.455)    0.300     0.710    0.0    1.264(0.753--2.122)    0.375     0.068    69.9   1.246(0.799--1.945)    0.332     0.095    64.2   1.104(0.885--1.377)    0.381     0.912    0.0
  Primary Liver Cancer                    7                   0.950(0.879--1.027)     0.199       0.444         0.0        0.919(0.778--1.086)    0.320     0.313    15.3   0.969(0.840--1.118)    0.666     0.103    43.2   0.951(0.831--1.088)    0.463     0.139    38.0   0.924(0.820--1.040)    0.191     0.641    0.0
  Prostate Cancer                         2                   0.801(0.660--0.971)     0.024       0.200         39.1       0.565(0.354--0.900)    0.016     0.234    29.5   0.761(0.509--1.137)    0.182     0.384    0.0    0.685(0.466--1.007)    0.054     0.340    0.0    0.757(0.568--1.008)    0.057     0.235    29.1
  PTC                                     4                   1.070(0.958--1.196)     0.230       0.520         0.0        0.639(0.321--1.272)    0.202     0.040    63.9   1.319(0.985--1.768)    0.063     0.042    63.4   1.189(1.009--1.402)    0.039     0.164    41.2   0.547(0.244--1.227)    0.143     0.006    75.6
  SCCHN                                   5                   1.160(0.956--1.407)     0.133       0.005         76.3       1.223(0.981--1.526)    0.074     0.134    46.3   1.147(1.003--1.311)    0.045     0.366    5.3    1.165(1.035--1.310)    0.011     0.349    10.0   1.187(0.807--1.744)    0.384     0.003    78.4
  other                                   5                   1.103(0.969--1.255)     0.136       0.173         37.3       1.673(1.163--2.408)    0.006     0.285    20.4   1.026(0.867--1.215)    0.763     0.758    0.0    1.093(0.930--1.285)    0.281     0.705    0.0    1.174(0.603--2.285)    0.638     0.007    71.8
  **Ethnicity**                                                                                                                                                                                                                                                                                                        
  Caucasian                              19                   1.069(1.015--1.126)     0.011       0.476         0.0        1.183(1.030--1.359)    0.017     0.193    22.0   1.077(0.978--1.185)    0.131     0.017    46.2   1.074(1.009--1.142)    0.024     0.135    27.0   1.162(1.014--1.331)    0.030     0.076    34.4
  Asian                                  28                   0.926(0.870--0.986)     0.017      \<0.001        68.5       0.868(0.762--0.989)    0.033    \<0.001   64.2   0.899(0.848--0.953)   \<0.001    0.06     31.3   0.899(0.822--0.983)    0.020     0.001    52.5   0.907(0.827--0.995)    0.039     0.001    62.9
  **Design**                                                                                                                                                                                                                                                                                                           
  HB                                     21                   0.903(0.845--0.964)     0.002      \<0.001        62.8       0.821(0.716--0.942)    0.005    \<0.001   60.3   0.908(0.829--0.995)    0.038     0.026    41.8   0.893(0.809--0.986)    0.025     0.001    57.4   0.869(0.795--0.951)    0.002     0.015    45.4
  PB                                     22                   1.046(0.983--1.113)     0.159       0.010         46.0       1.108(0.940--1.306)    0.223     0.008    47.1   1.027(0.941--1.122)    0.548     0.023    41.4   1.044(0.961--1.134)    0.307     0.033    39.0   1.087(0.940--1.256)    0.261     0.001    56.4
  **Sample size**                                                                                                                                                                                                                                                                                                      
  ≥1000                                  16                   1.015(0.947--1.088)     0.676      \<0.001        75.0       1.074(0.924--1.247)    0.352    \<0.001   73.1   0.949(0.880--1.022)    0.167     0.024    45.6   0.976(0.895--1.064)    0.583    \<0.001   63.6   1.085(0.967--1.218)    0.164     0.001    69.8
  \<1000                                 31                   0.947(0.882--1.016)     0.128       0.001         51.6       0.836(0.712--0.982)    0.029     0.010    41.3   1.015(0.913--1.129)    0.783     0.005    44.9   0.993(0.897--1.100)    0.898     0.001    50.4   0.841(0.752--0.940)    0.002     0.042    33.1
  **HWE**                                                                                                                                                                                                                                                                                                              
  Yes                                    42                   0.982(0.931--1.037)     0.517      \<0.001        66.1       0.940(0.833--1.060)    0.315    \<0.001   62.4   0.986(0.920--1.056)    0.683     0.001    47.0   0.981(0.912--1.057)    0.619    \<0.001   58.2   0.959(0.875--1.051)    0.368    \<0.001   59.7

ESCC: esophageal squamous cell carcinoma; PTC: papillary thyroid carcinoma; SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; *P*: p value; *P-H*:P value of Q for heterogeneity test; *I^2^*: 0--25%, no heterogeneity; 25--50%, modest heterogeneity; 50%, high heterogeneity;

Number of studies involved Random effects model was used when P value of Q for heterogeneity test (P-H)\<0.05 or *I^2^*\>50%; otherwise, fixed effect model was used.

However, in the stratified analysis by cancer type, the C allele and CC genotype of rs2910164 were found to be associated with an inverse risk of bladder cancer under all genetic models, except for the recessive model (C vs. G: OR = 0.838, 95% CI = 0.762--0.921, *P* ~H = ~0.324; CC vs. GG: OR = 0.724, 95% CI = 0.587--0.893, *P* ~H = ~0.241; GC vs. GG: OR = 0.789, 95% CI = 0.689--0.904, *P* ~H = ~0.526; CC+GC vs. GG: OR = 0.781, 95% CI = 0.687--0.889, *P* ~H~ \<0.290), cervical cancer under all genetic models (C vs. G: OR = 0.719, 95% CI = 0.620--0.839, *P* ~H = ~0.796; CC vs. GG: OR = 0.503, 95% CI = 0.370--0.684, *P* ~H = ~0.814; GC vs. GG: OR = 0.721, 95% CI = 0.545--0.953, *P* ~H = ~0.254; CC+GC vs. GG: OR = 0.632, 95% CI = 0.485--0.823, *P* ~H = ~0.382; CC vs. GC+GG: OR = 0.654, 95% CI = 0.520--0.822, *P* ~H = ~0.359), colorectal cancer under allelic contrast, heterozygote comparison and the dominant model (C vs. G: OR = 0.912, 95% CI = 0.833--0.999, *P* ~H = ~0.324; GC vs. GG: OR = 0.854, 95% CI = 0.740--0.985, *P* ~H = ~0.376; CC+GC vs. GG: OR = 0.859, 95% CI = 0.750--0.984, *P* ~H = ~0.294) and prostate cancer under allelic contrast and homozygote comparison (C vs. G: OR = 0.801, 95% CI = 0.660--0.971, *P* ~H = ~0.200; CC vs. GG: OR = 0.565, 95% CI = 0.354--0.900, *P* ~H = ~0.234). In addition, rs2910164 was found to be associated with risks of PTC and SCCHN in the heterozygote comparison (CC+GC vs. GG: OR = 1.189, 95% CI = 1.009--1.402, *P* ~H = ~0.164) and the dominant model (GC vs. GG: OR = 1.147, 95% CI = 1.003--1.311, *P* ~H = ~0.366). Nevertheless, the direction of ORs in the two cancers was opposite to that of the former four cancers.

When stratified analysis was performed by ethnicity of study population, rs2910164 C allele and CC genotype were shown to be associated with substantial decrease in cancer risk in Asian populations under all genetic models. On the contrary, Caucasian C or CC carriers were more susceptible to cancers under all genetic models, except for heterozygote comparison. Further subgroup analysis revealed the C allele or CC genotype to be associated with decreased cancer risk in studies of hospital-based study design for all genetic models, but not in studies of population based study design. When stratified on the basis of sample size, the CC genotype had an effect of decreased cancer risk among small size subgroups compared with GG genotype or G allele carriers.

### miR-196a2 rs11614913 {#s3b2}

The miR-196a2 rs11614913 polymorphism was analyzed in 38 comparisons with 16,414 cases and 19,465 controls. We also observed a wide variation of the T allele frequency across different ethnicities (Asian: 49.8%, 95% CI = 45.3%--54.3%; Caucasian: 38.8%, 95% CI = 35.9%--41.7%; *P = *0.002).

[Table 3](#pone-0079584-t003){ref-type="table"} summarizes the results from the meta-analysis of miR-196a2 rs11614913 and cancer risk. In the overall analysis, we found a significant association between rs11614913 and reduced cancer risk in the allelic contrast (OR = 0.949, 95% CI = 0.902--0.998, *P* ~H~ \<0.001), homozygote comparison (OR = 0.861, 95% CI = 0.772--0.959 *P* ~H~\<0.001) and recessive model (OR = 0.865, 95% CI = 0.802--0.934, *P* ~H = ~0.002). Removing four studies with genotype frequencies in controls that deviated from HWE did not alter the pooled results [@pone.0079584-Mittal1], [@pone.0079584-Alshatwi1], [@pone.0079584-Linhares1], [@pone.0079584-George1].

10.1371/journal.pone.0079584.t003

###### Meta-analysis of miR-196a2 rs11614913 polymorphism with cancer risk.

![](pone.0079584.t003){#pone-0079584-t003-3}

  Variables               n[a](#nt105){ref-type="table-fn"}         T vs. C         TT vs. CC   CT vs. CC   TT+CT vs. CC      TT vs. CT+CC                                                                                                                                                                         
  ---------------------- ----------------------------------- --------------------- ----------- ----------- -------------- --------------------- ------- --------- ------ --------------------- ------- --------- ------ --------------------- --------- --------- ------ --------------------- --------- --------- -------
  **Total**                              38                   0.949(0.902--0.998)     0.044      \<0.001        58.2       0.861(0.772--0.959)   0.007   \<0.001   58.7   1.033(0.951--1.123)   0.441   \<0.001   56.6   0.984(0.909--1.065)    0.685    \<0.001   60.0   0.865(0.802--0.934)   \<0.001    0.002    45.2
  **Cancer type**                                                                                                                                                                                                                                                                                                  
  Bladder Cancer                          2                   1.032(0.906--1.174)     0.639       0.562         0.0        0.961(0.724--1.277)   0.786    0.224    32.4   1.192(0.837--1.696)   0.331    0.106    61.7   1.102(0.915--1.327)    0.307     0.171    46.5   0.738(0.320--1.701)    0.476     0.100    63.1
  Breast Cancer                           8                   0.978(0.868--1.102)     0.716       0.002         68.3       0.903(0.699--1.167)   0.436    0.004    66.9   0.976(0.888--1.074)   0.623    0.12     38.9   0.989(0.841--1.164)    0.898     0.014    60.3   0.915(0.765--1.095)    0.334     0.031    54.5
  Colorectal Cancer                       6                   0.910(0.794--1.043)     0.177       0.061         52.6       0.754(0.627--0.907)   0.003    0.108    44.6   0.878(0.755--1.021)   0.091    0.168    35.9   0.848(0.735--0.979)    0.025     0.082    48.9   0.838(0.721--0.974)    0.021     0.165    36.3
  ESCC                                    2                   0.863(0.551--1.351)     0.518       0.001         90.6       0.685(0.209--2.245)   0.532   \<0.001   93.9   1.166(0.692--1.962)   0.564    0.030    78.7   1.020(0.537--1.935)    0.953     0.005    87.3   0.610(0.268--1.390)    0.240     0.001    91.4
  Gastric Cancer                          2                   0.893(0.778--1.024)     0.104       0.230         30.5       0.803(0.608--1.062)   0.125    0.306    4.5    0.839(0.653--1.077)   0.167    0.163    48.5   0.819(0.647--1.037)    0.097     0.162    48.8   0.894(0.722--1.107)    0.305     0.698     0.0
  Lung Cancer                             4                   0.893(0.821--0.971)     0.008       0.149         43.8       0.794(0.672--0.938)   0.007    0.259    25.5   0.991(0.771--1.274)   0.945    0.059    59.7   0.935(0.745--1.175)    0.565     0.075    56.6   0.842(0.737--0.962)    0.011     0.201    0.201
  Primary Liver Cancer                    5                   0.890(0.767--1.032)     0.123       0.034         61.7       0.790(0.589--1.061)   0.117    0.041    59.8   0.873(0.754--1.010)   0.068    0.776    0.0    0.859(0.748--0.986)    0.030     0.334    12.5   0.871(0.690--1.100)    0.248     0.043    59.4
  SCCHN                                   4                   1.067(0.965--1.179)     0.205       0.442         0.0        1.241(0.841--1.831)   0.276    0.099    63.3   1.490(0.835--2.658)   0.177    0.006    86.7   1.123(0.851--1.481)    0.413     0.006    76.1   0.948(0.797--1.127)    0.544     0.683     0.0
  other                                   5                   1.026(0.928--1.135)     0.613       0.352         9.5        0.966(0.776--1.201)   0.754    0.491    0.0    1.306(1.106--1.542)   0.002    0.188    34.9   1.212(1.035--1.419)    0.017     0.159    39.3   0.853(0.716--1.017)    0.076     0.720     0.0
  **Ethnicity**                                                                                                                                                                                                                                                                                                    
  Caucasian                              14                   0.981(0.894--1.076)     0.683       0.002         61.8       0.934(0.766--1.138)   0.496    0.003    61.7   1.023(0.946--1.108)   0.565     0.3     14.7   0.989(0.895--1.092)    0.825     0.048    42.3   0.918(0.788--1.070)    0.276     0.035    47.1
  Asian                                  24                   0.934(0.879--0.991)     0.025       0.001         55.0       0.827(0.727--0.940)   0.004    0.001    55.5   1.043(0.924--1.177)   0.500   \<0.001   65.9   0.986(0.878--1.107)    0.808    \<0.001   66.6   0.845(0.773--0.923)   \<0.001    0.011    44.1
  **Design**                                                                                                                                                                                                                                                                                                       
  HB                                     21                   0.918(0.855--0.986)     0.019      \<0.001        64.5       0.849(0.726--0.993)   0.040   \<0.001   69.5   0.997(0.881--1.127)   0.956   \<0.001   63.4   0.946(0.842--1.064)    0.355    \<0.001   65.6   0.848(0.763--0.942)    0.002     0.001    56.4
  PB                                     14                   0.963(0.916--1.012)     0.132       0.152         29.2       0.869(0.783--0.966)   0.009    0.553    0.0    1.064(0.943--1.201)   0.314    0.024    48.9   1.011(0.907--1.127)    0.843     0.022    48.5   0.908(0.832--0.991)    0.031     0.525     0.0
  **Sample size**                                                                                                                                                                                                                                                                                                  
  ≥1000                                  11                   0.941(0.904--0.979)     0.003       0.131         33.5       0.880(0.811--0.955)   0.002    0.143    32.0   0.964(0.902--1.031)   0.287    0.085    39.6   0.936(0.857--1.021)    0.137     0.048    45.8   0.904(0.845--0.966)    0.003     0.593     0.0
  \<1000                                 27                   0.966(0.889--1.050)     0.416      \<0.001        65.0       0.854(0.709--1.029)   0.098   \<0.001   65.4   1.092(0.959--1.243)   0.183   \<0.001   60.3   0.835(0.769--0.907)   \<0.001   \<0.001   64.4   0.833(0.729--0.952)    0.007    \<0.001   55.3
  **HWE**                                                                                                                                                                                                                                                                                                          
  Yes                                    32                   0.929(0.884--0.977)     0.004      \<0.001        55.1       0.851(0.763--0.948)   0.003   \<0.001   58.7   0.990(0.914--1.073)   0.815    0.001    50.9   0.948(0.874--1.028)    0.196    \<0.001   56.8   0.863(0.800--0.931)   \<0.001    0.004    44.7

ESCC: esophageal squamous cell carcinoma; SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; *P*: p value; *P-H*: P value of Q for heterogeneity test; *I^2^*: 0--25%, no heterogeneity; 25--50%, modest heterogeneity; 50%, high heterogeneity;

Number of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H) \<0.05 or *I^2^*\>50%; otherwise, fixed effect model was used.

In subgroup analysis by cancer type, significant association between rs11614913 and decreased cancer risk was found for lung cancer (T vs. C: OR = 0.893, 95% CI = 0.821--0.971, *P* ~H = ~0.149; TT vs. CC: OR = 0.794, 95% CI = 0.627--0.938, *P* ~H = ~0.259; TT vs. CT+CC: OR = 0.842, 95% CI = 0.737--0.962, *P* ~H = ~0.201) and colorectal cancer (TT vs. CC: OR = 0.754, 95% CI = 0.627--0.907, *P* ~H = ~0.108; TT+CT vs. CC: OR = 0.848, 95% CI = 0.735--0.979, *P* ~H = ~0.082; TT vs. CT+CC: OR = 0.838, 95% CI = 0.721--0.974, *P* ~H = ~0.165). For liver cancer, T allele carriers showed decreased cancer susceptibility compared with homozygote CC (OR = 0.859, 95% CI = 0.748--0.986, *P* ~H = ~0.334). However, no association was found between rs11614913 and bladder cancer, breast cancer, ESCC, gastric cancer, or SCCHN.

In ethnic subgroup analysis, a strong association was found between rs11614913 and cancer risk in the allelic contrast, the homozygote comparison, and the recessive model among Asians, whereas negative results were obtained for Caucasians in all genetic models. With respect to the control source, decreased risk was observed in both the hospital- and population-based controls for the homozygote comparison and the recessive model. We also found a reduced risk for allelic contrast in hospital-based studies. In stratified analysis by sample size, significant association of decreased cancer risk was found in both of the subgroups.

### miR-499 rs3746444 {#s3b3}

For miR-499 rs3746444, 21 comparisons with 8,888 cases and 10,292 controls were included. No significant difference in C allele frequency between Asians and Caucasians was observed (Asian: 22.2%, 95% CI = 16.7%--27.7%; Caucasian: 29.9%, 95% CI = 14.4%--45.4%; *P = *0.178).

The results of the meta-analysis for miR-499 rs3746444 and the risk of cancer are presented in [Table 4](#pone-0079584-t004){ref-type="table"}. Overall, we observed that rs3746444 could decrease the cancer risk in the allelic contrast (OR = 1.106, 95% CI = 1.005--1.218, *P* ~H~ \<0.001) and the dominant model (OR = 1.148, 95% CI = 1.020--1.292, *P* ~H~ \<0.001). However, this association disappeared after the exclusion of six studies [@pone.0079584-Mittal1], [@pone.0079584-Orsos1], [@pone.0079584-Ma2], [@pone.0079584-Zhou4], [@pone.0079584-George1], [@pone.0079584-Christensen1], whose genotypic distribution in controls was derived from HWE.

10.1371/journal.pone.0079584.t004

###### Meta-analysis of miR-499 rs3746444 polymorphism with cancer risk.

![](pone.0079584.t004){#pone-0079584-t004-4}

  Variables               n[a](#nt108){ref-type="table-fn"}         C vs. T         CC vs. TT   TC vs. TT   CC+TC vs. TT      CC vs. TC+TT                                                                                                                                                                 
  ---------------------- ----------------------------------- --------------------- ----------- ----------- -------------- --------------------- ------- ------- ------ --------------------- ------- --------- ------ --------------------- ------- --------- ------ --------------------- ------- ------- ------
  **Total**                              21                   1.106(1.005--1.218)     0.040      \<0.001        67.2       1.167(0.969--1.405)   0.103   0.042   38.3   1.126(0.985--1.288)   0.081   \<0.001   71.9   1.148(1.020--1.292)   0.022   \<0.001   69.0   1.100(0.903--1.339)   0.344   0.007   49.4
  **Cancer type**                                                                                                                                                                                                                                                                                          
  Breast Cancer                           4                   1.101(1.006--1.204)     0.036       0.214         33.0       1.165(0.915--1.482)   0.215   0.189   37.1   1.163(0.952--1.420)   0.140    0.047    62.3   1.150(0.973--1.359)   0.102    0.102    51.7   1.065(0.712--1.595)   0.758   0.059   59.8
  Colorectal Cancer                       2                   1.136(0.938--1.375)     0.192       0.161         49.1       1.557(0.670--3.621)   0.304   0.096   63.9   0.867(0.541--1.390)   0.554    0.100    63.0   1.045(0.831--1.314)   0.705    0.964    0.0    1.645(0.611--4.428)   0.325   0.047   74.6
  Lung Cancer                             2                   0.963(0.822--1.129)     0.643       0.828         0.0        0.880(0.538--1.439)   0.610   0.919   0.0    0.981(0.812--1.185)   0.843    0.595    0.0    0.970(0.809--1.163)   0.742    0.682    0.0    0.874(0.537--1.424)   0.589   0.836   0.0
  Primary Liver Cancer                    4                   1.094(0.737--1.623)     0.656      \<0.001        83.3       1.187(0.560--2.516)   0.655   0.017   70.5   1.007(0.696--1.458)   0.970    0.048    62.1   1.074(0.685--1.683)   0.757    0.004    77.2   1.201(0.675--2.136)   0.533   0.065   58.6
  SCCHN                                   3                   1.290(0.593--2.804)     0.521      \<0.001        95.4       1.774(0.429--7.328)   0.429   0.030   78.6   1.220(0.527--2.821)   0.643   \<0.001   94.8   1.289(0.751--2.215)   0.357   \<0.001   91.9   1.685(0.503--5.643)   0.398   0.061   71.5
  other                                   6                   1.103(0.988--1.231)     0.081       0.124         42.2       1.078(0.823--1.413)   0.585   0.494   0.0    1.280(0.935--1.753)   0.123   \<0.001   77.7   1.223(0.947--1.579)   0.124    0.006    69.7   0.946(0.730--1.226)   0.675   0.121   42.6
  **Ethnicity**                                                                                                                                                                                                                                                                                            
  Caucasian                               7                   1.003(0.926--1.086)     0.951       0.197         31.8       1.110(0.912--1.352)   0.299   0.233   26.9   0.939(0.846--1.042)   0.236    0.143    39.4   0.997(0.908--1.095)   0.952    0.166    34.3   1.139(0.948--1.368)   0.166   0.088   47.8
  Asian                                  14                   1.142(0.999--1.305)     0.052      \<0.001        71.5       1.169(0.894--1.529)   0.253   0.036   44.7   1.234(1.035--1.471)   0.019   \<0.001   73.9   1.220(1.032--1.442)   0.020   \<0.001   73.7   1.039(0.781--1.381)   0.794   0.009   53.4
  **Design**                                                                                                                                                                                                                                                                                               
  HB                                      9                   1.188(0.962--1.465)     0.109      \<0.001        82.6       1.283(0.910--1.809)   0.156   0.036   53.3   1.163(0.899--1.504)   0.250   \<0.001   80.5   1.216(0.965--1.533)   0.097   \<0.001   80.7   1.224(1.004--1.491)   0.045   0.101   39.2
  PB                                     10                   1.055(0.985--1.130)     0.127       0.088         40.4       1.061(0.881--1.278)   0.533   0.369   7.9    1.142(0.969--1.346)   0.114    0.001    67.4   1.110(0.961--1.282)   0.156    0.006    60.8   0.968(0.808--1.160)   0.726   0.097   41.5
  **Sample size**                                                                                                                                                                                                                                                                                          
  ≥1000                                   6                   1.031(0.930--1.143)     0.560       0.039         57.4       1.135(0.946--1.362)   0.173   0.259   23.3   0.992(0.913--1.077)   0.840    0.076    49.9   1.015(0.901--1.142)   0.809    0.049    55.1   1.135(0.948--1.359)   0.167   0.293   18.5
  \<1000                                 15                   1.157(0.996--1.343)     0.056      \<0.001        68.7       1.165(0.869--1.562)   0.307   0.030   46.1   1.225(0.985--1.523)   0.068   \<0.001   73.7   1.241(1.038--1.485)   0.018   \<0.001   68.5   1.043(0.762--1.429)   0.791   0.003   58.5
  **HWE**                                                                                                                                                                                                                                                                                                  
  Yes                                    14                   1.049(0.939--1.172)     0.397      \<0.001        67.8       1.063(0.902--1.252)   0.465   0.275   16.4   1.109(0.952--1.293)   0.184   \<0.001   74.0   1.094(0.947--1.265)   0.222   \<0.001   73.2   1.006(0.857--1.181)   0.938   0.111   33.0

SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; *P*: p value; *P-H*: P value of Q for heterogeneity test; *I^2^*: 0--25%, no heterogeneity; 25--50%, modest heterogeneity; 50%, high heterogeneity;

Number of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H)\<0.05 or *I^2^*\>50%; otherwise, fixed effect model was used.

In stratified analysis by cancer type, significant associations were only maintained in breast cancer under allelic contrast (OR = 1.101, 95% CI = 1.006--1.204, *P* ~H = ~0.214), but no significant association was observed with colorectal cancer, lung cancer, liver cancer, SCCHN, and other cancers under any genetic model. Subgroup analysis by ethnicity showed a decreased cancer risk in the Asian population (TC vs. TT: OR = 1.234, 95% CI = 1.035--1.471, *P* ~H~ \<0.001; TC+CC vs. TT: OR = 1.220, 95% CI = 1.032--1.442, *P* ~H~ \<0.001), but not in the Caucasian population. Based on study design, studies with hospital-based controls showed elevated risk (CC vs. TC+TT: OR = 1.224, 95% CI = 1.004--1.491, *P* ~H~ = 0.045). However, studies with population-based controls showed no significant association. Further subgroup analysis by sample size revealed increased cancer risks only in a small sample group using the dominant model (TC+CC vs. TT: OR = 1.241, 95% CI = 1.038--1.485, *P* ~H~ \<0.001).

### miR-149 rs2292832 {#s3b4}

Twelve comparisons with 5926 cases and 5961 controls assessed for the association between miR-149 rs2292832 polymorphism and cancer risk. The frequency of T allele was significant higher in Asian population compared to that in Caucasian population (Asian: 65.1%, 95% CI = 53.2%--77.0%; Caucasian: 30.6%, 95% CI = 25.2%--36.0%; *P = *0.003).

Overall, none of the genetic models produced significant association between rs2292832 and cancer risk. Similarly, no positive result was found in most of the subgroups, except that homozygote TT had an effect of increasing risk of other cancers compared with C allele carriers (OR = 1.388, 95% CI = 1.083--1.778, *P* ~H = ~0.427) and significant association with increased cancer risk was also found in small sample group for allelic contrast (OR = 1.106, 95% CI = 1.012--1.209, *P* ~H = ~0.461) and recessive model (OR = 1.217, 95% CI = 1.078--1.373, *P* ~H = ~0.380). These results are summarized in [Table 5](#pone-0079584-t005){ref-type="table"}.

10.1371/journal.pone.0079584.t005

###### Meta-analysis of miR-149 rs2292832 polymorphism with cancer risk.

![](pone.0079584.t005){#pone-0079584-t005-5}

  Variables            n[a](#nt111){ref-type="table-fn"}         T vs. C         TT vs. CC   CT vs. CC   TT+CT vs. CC      TT vs. CT+CC                                                                                                                                                            
  ------------------- ----------------------------------- --------------------- ----------- ----------- -------------- --------------------- ------- ------- ------ --------------------- ------- ------- ----- --------------------- ------- ------- ------ --------------------- ------- ------- ------
  **Total**                           12                   1.022(0.966--1.082)     0.449       0.283         16.8       1.002(0.880--1.140)   0.980   0.529   0.0    0.950(0.862--1.048)   0.306   0.971   0.0   0.975(0.892--1.065)   0.571   0.979   0.0    1.082(0.990--1.183)   0.083   0.109   36.2
  **Cancer type**                                                                                                                                                                                                                                                                                  
  Breast Cancer                        2                   1.078(0.860--1.350)     0.515       0.121         58.4       1.043(0.794--1.369)   0.763   0.361   0.0    0.977(0.821--1.162)   0.789   0.907   0.0   0.991(0.839--1.169)   0.911   0.656   0.0    1.170(0.819--1.670)   0.388   0.123   58.0
  Colorectal Cancer                    3                   1.063(0.935--1.207)     0.352       0.979         0.0        1.072(0.807--1.424)   0.631   0.619   0.0    0.856(0.660--1.109)   0.238   0.996   0.0   0.942(0.738--1.202)   0.629   0.995   0.0    1.161(0.972--1.386)   0.100   0.628   0.0
  Lung Cancer                          2                   1.090(0.762--1.560)     0.638       0.073         68.8       1.259(0.547--2.902)   0.588   0.058   72.1   0.986(0.764--1.273)   0.915   0.562   0.0   0.995(0.782--1.266)   0.966   0.238   28.2   1.234(0.598--2.545)   0.569   0.071   69.4
  SCCHN                                3                   0.957(0.853--1.074)     0.458       0.688         0.0        0.863(0.661--1.126)   0.277   0.619   0.0    0.976(0.826--1.154)   0.776   0.323   0.0   0.966(0.839--1.111)   0.626   0.651   0.0    0.930(0.753--1.149)   0.503   0.742   0.0
  other                                2                   1.200(0.997--1.444)     0.054       0.259         21.6       1.181(0.790--1.767)   0.417   0.271   17.3   0.825(0.550--1.239)   0.354   0.409   0.0   0.992(0.677--1.452)   0.965   0.312   2.0    1.388(1.083--1.778)   0.010   0.427   0.0
  **Ethnicity**                                                                                                                                                                                                                                                                                    
  Caucasian                            4                   1.014(0.904--1.139)     0.810       0.220         33.9       1.261(0.749--2.123)   0.383   0.102   56.2   0.991(0.848--1.160)   0.914   0.688   0.0   1.000(0.876--1.143)   0.996   0.767   0.0    1.286(0.761--2.171)   0.348   0.082   59.9
  Asian                                8                   1.025(0.960--1.095)     0.463       0.255         22.0       0.986(0.851--1.143)   0.852   0.745   0.0    0.925(0.817--1.048)   0.222   0.949   0.0   0.955(0.849--1.075)   0.447   0.945   0.0    1.085(0.986--1.193)   0.094   0.154   34.3
  **Design**                                                                                                                                                                                                                                                                                       
  HB                                   4                   0.984(0.891--1.087)     0.756       0.599         0.0        0.901(0.718--1.130)   0.368   0.733   0.0    0.960(0.821--1.123)   0.613   0.532   0.0   0.963(0.843--1.100)   0.577   0.831   0.0    1.012(0.860--1.190)   0.890   0.451   0.0
  PB                                   6                   1.029(0.957--1.107)     0.437       0.156         37.6       1.007(0.854--1.187)   0.934   0.645   0.0    0.943(0.826--1.077)   0.387   0.923   0.0   0.970(0.855--1.101)   0.636   0.917   0.0    1.092(0.979--1.217)   0.116   0.079   49.4
  **Sample size**                                                                                                                                                                                                                                                                                  
  ≥1000                                3                   0.967(0.898--1.042)     0.383       0.901         0.0        0.924(0.778--1.098)   0.370   0.892   0.0    0.984(0.877--1.104)   0.781   0.950   0.0   0.971(0.871--1.084)   0.604   0.920   0.0    0.940(0.823--1.073)   0.357   0.891   0.0
  \<1000                               9                   1.106(1.012--1.209)     0.027       0.461         0.0        1.111(0.914--1.350)   0.292   0.442   0.0    0.870(0.724--1.046)   0.138   0.957   0.0   0.981(0.845--1.139)   0.802   0.902   0.0    1.217(1.078--1.373)   0.001   0.380   0.0
  **HWE**                                                                                                                                                                                                                                                                                          
  Yes                                 10                   1.029(0.970--1.091)     0.346       0.261         19.8       1.019(0.892--1.164)   0.781   0.534   0.0    0.957(0.867--1.057)   0.389   0.977   0.0   0.981(0.893--1.078)   0.693   0.973   0.0    1.095(0.997--1.202)   0.058   0.090   40.2

SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; *P*: p value; *P-H*: P value of Q for heterogeneity test; *I^2^*: 0--25%, no heterogeneity; 25--50%, modest heterogeneity; 50%, high heterogeneity;

Number of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H)\<0.05 or *I^2^*\>50%; otherwise, fixed effect model was used.

### miR-27a rs895919 {#s3b5}

For miR-27a rs895919, we collected nine comparisons with 4662 cases and 5625 controls. No significant difference in G allele frequency between Asians and Caucasians was observed (Asian: 32,4%, 95% CI = 21.2%--43.6%; Caucasian: 32.1%, 95% CI = 28.7%--35.6%; *P = *0.949).

Overall, there was no significant association observed in all comparisons. However, in subgroup analysis, a decreased risk was found in other cancers (AG vs. AA: OR = 0.828, 95% CI = 0.698--0.982, *P* ~H~ = 0.030; GG+AG vs. AA: OR = 0.821, 95% CI = 0.698--0.966, *P* ~H~ = 0.017), large sample groups (G vs. A: OR = 0.875, 95% CI = 0.811--0.945, *P* ~H~ = 0.001; AG vs. AA: OR = 0.806, 95% CI = 0.726--0.895, *P* ~H~ \<0.001; GG+AG vs. AA: OR = 0.815, 95% CI = 0.738--0.900, *P* ~H~ \<0.001), the Caucasian population (AG vs. AA: OR = 0.879, 95% CI = 0.792--0.975, *P* ~H~ = 0.015) and population-based studies (G vs. A: OR = 0.900, 95% CI = 0.830--0.975, *P* ~H~ = 0.010) ([Table 6](#pone-0079584-t006){ref-type="table"}).

10.1371/journal.pone.0079584.t006

###### Meta-analysis of miR-27a rs895919 polymorphism with cancer risk.

![](pone.0079584.t006){#pone-0079584-t006-6}

  Variables          n[a](#nt114){ref-type="table-fn"}         G vs. A         GG vs. AA   AG vs. AA   GG+AG vs. AA      GG vs. AG+AA                                                                                                                                                                    
  ----------------- ----------------------------------- --------------------- ----------- ----------- -------------- --------------------- ------- --------- ------- --------------------- --------- ------- ------ --------------------- --------- ------- ------ --------------------- ------- ------- ------
  **Total**                          9                   0.945(0.853--1.048)     0.284       0.008         61.1       0.897(0.714--1.127)   0.352    0.017    56.9    0.980(0.836--1.149)    0.805    0.001   68.6   0.959(0.828--1.112)    0.581    0.002   67.1   0.891(0.722--1.101)   0.286   0.023   55.0
  **Cancer type**                                                                                                                                                                                                                                                                                        
  Breast Cancer                      4                   0.930(0.864--1.002)     0.056       0.155         42.7       0.915(0.775--1.081)   0.295    0.419     0.0    1.009(0.788--1.292)    0.944    0.003   78.5   0.977(0.797--1.199)    0.825    0.014   71.6   0.929(0.793--1.087)   0.357   0.165   41.0
  Gastric Cancer                     2                   1.029(0.587--1.803)     0.922       0.001         90.9       0.717(0.122--4.227)   0.713   \<0.001   92.6    1.152(0.765--1.734)    0.499    0.078   67.8   1.116(0.629--1.977)    0.708    0.009   85.2   0.668(0.139--3.220)   0.616   0.001   91.0
  other                              3                   0.862(0.759--0.979)     0.022       0.513         0.0        0.794(0.586--1.077)   0.139    0.643     0.0    0.828(0.698--0.982)    0.030    0.153   46.7   0.821(0.698--0.966)    0.017    0.259   26.1   0.865(0.645--1.161)   0.335   0.512   0.0
  **Ethnicity**                                                                                                                                                                                                                                                                                          
  Caucasian                          4                   0.929(0.862--1.002)     0.055       0.157         42.4       0.924(0.780--1.094)   0.359    0.421     0.0    0.879(0.792--0.975)    0.015    0.116   49.2   0.914(0.782--1.068)    0.258    0.099   52.1   0.983(0.836--1.156)   0.84    0.647   0.0
  Asian                              5                   0.938(0.769--1.144)     0.526       0.004         74.0       0.788(0.485--1.280)   0.336    0.004    74.4    1.064(0.789--1.435)    0.685    0.001   77.8   1.008(0.762--1.334)    0.954    0.002   77.1   0.744(0.480--1.154)   0.187   0.006   72.4
  **Design**                                                                                                                                                                                                                                                                                             
  HB                                 5                   0.938(0.765--1.149)     0.536       0.004         73.9       0.801(0.483--1.329)   0.390    0.003    0.003   0.964(0.760--1.223)    0.762    0.022   65.0   0.946(0.739--1.212)    0.662    0.008   70.8   0.819(0.529--1.270)   0.373   0.013   68.5
  PB                                 3                   0.900(0.830--0.975)     0.010       0.745         0.0        0.864(0.722--1.034)   0.112    0.970     0.0    0.978(0.726--1.316)    0.881    0.004   81.9   0.921(0.742--1.143)    0.455    0.039   69.2   0.889(0.750--1.053)   0.174   0.197   38.4
  **Sample size**                                                                                                                                                                                                                                                                                        
  ≥1000                              3                   0.875(0.811--0.945)     0.001       0.575         0.0        0.855(0.717--1.018)   0.078    0.936     0.0    0.806(0.726--0.895)   \<0.001   0.200   37.9   0.815(0.738--0.900)   \<0.001   0.296   17.8   0.944(0.798--1.117)   0.503   0.790   0.0
  \<1000                             6                   1.008(0.857--1.184)     0.927       0.017         63.6       0.895(0.583--1.374)   0.611    0.004    71.0    1.127(0.985--1.291)    0.082    0.186   33.4   1.087(0.956--1.236)    0.205    0.080   49.2   0.817(0.547--1.220)   0.323   0.004   70.9
                                                                                                                                                                                                                                                                                                         

HB: hospital based; PB: population based; OR: odds ratio; CI: confidence interval; *P*: p value; *P-H*: P value of Q for heterogeneity test; *I^2^*:0--25%, no heterogeneity; 25--50%, modest heterogeneity; 50%, high heterogeneity;

Number of studies involved. Random effects model was used when P value of Q for heterogeneity test (P-H) \<0.05 or *I^2^*\>50%; otherwise, fixed effect model was used.

Test of Heterogeneity {#s3c}
---------------------

Heterogeneity between studies was observed in overall comparisons and subgroup analyses across the studies of rs2910164, rs11614913, rs3746444, and rs895919. Then we evaluated the source of heterogeneity for allelic contrast by cancer type, ethnicity, source of controls and sample size. For rs2910164, cancer type ( = 51.58, df = 11, *P*\<0.001), ethnicity ( = 24.43, df = 1, *P*\<0.001) and control type ( = 29.55, df = 3, *P*\<0.001) provided potential sources of between-study heterogeneity. For rs11614913, cancer type ( = 17.84, df = 8, *P = *0.002) and control type ( = 13.08, df = 3, *P = *0.004) was found to contribute to substantial heterogeneity. For rs3746444, ethnicity ( = 4.92, df = 1, *P = *0.027) and sample size ( = 4.6, df = 1, *P = *0.032) contributed substantially to heterogeneity. For miR-27a rs895919, sample size ( = 5.74, df = 1, *P = *0.017) was the main source of between-study heterogeneity.

Sensitivity Analysis {#s3d}
--------------------

Influence of each study involved in the meta-analysis on the pooled ORs for each of the studied SNPs was examined by repeating the meta-analysis and omitting each study one at a time. The corresponding pooled ORs were not materially altered.

Publication Bias {#s3e}
----------------

We conducted Begg's funnel plot and Egger's test to assess the publication bias of included studies for all the SNPs. For miR-146a rs2910164 ([Figure S1](#pone.0079584.s001){ref-type="supplementary-material"}), miR-196a2 rs11614913 ([Figure S2](#pone.0079584.s002){ref-type="supplementary-material"}) and miR-499 rs3746444 ([Figure S3](#pone.0079584.s003){ref-type="supplementary-material"}), no evidence of publication bias was suggested in the results from the Begg's funnel plot and Egger's test for allelic contrast. Similar results were observed in other models (data not shown). However, for miR-149 rs2292832 ([Figure S4](#pone.0079584.s004){ref-type="supplementary-material"}), significant publication bias was found in allelic contrast (*P* = 0.006), homozygote comparison (*P* = 0.005) and the recessive model (*P* = 0.007). For miR-27a rs895919 ([Figure S5](#pone.0079584.s005){ref-type="supplementary-material"}), no evidence of publication bias was detected for allelic contrast, but publication bias was found in the heterozygote comparison (*P* = 0.039), probably due to the small number of included studies.

Discussion {#s4}
==========

In the present study, we performed five independent meta-analyses to investigate the association between cancer risk and polymorphisms in miRNA (miR-146a rs2910164, miR-196a2 rs11614913, miR-499 rs3746444, miR-149 rs2292832, and miR-27a rs895919). The results demonstrated that the rs2910164 C allele or CC genotype was a protective factor for bladder cancer, prostate cancer, cervical cancer and colorectal cancer, but a risk factor for PTC and SCCHN. The significant association between rs2910164 and cancer risk was observed in both Asians and Caucasians, although in opposite directions. The miR-196a2 rs11614913 T allele was observed to be significantly associated with reduced cancer risk, especially for lung cancer and colorectal cancer, particularly in the Asian population. The miR-499 rs3746444 C allele increased cancer risk in the allelic contrast model and in the dominant model, especially in breast cancer. Nevertheless, this association was only observed in Asians, not in Caucasians. On the other hand, mir-149 rs2292832 and miR-27a rs895919 were not significantly related to cancer susceptibility.

Several meta-analyses have been conducted on a single miRNA SNP [@pone.0079584-Wang3]--[@pone.0079584-Wang12] or several miRNA SNPs [@pone.0079584-Xu1], [@pone.0079584-Wang13]--[@pone.0079584-Xu5] associated with the risk of cancer(s). However, none of the meta-analyses have comprehensively covered all the studies on a particular miRNA SNP or all the commonly studied miRNA SNPs. In this study, we included all the papers published to date on the five commonly studied miRNA SNPs associated with cancer susceptibility, and in so doing incorporated more studies and cancer types than the previously published meta-analyses. For example, compared to the recently published meta-analysis by He *et al*. [@pone.0079584-He1], our paper included several new studies for each of the miRNA SNPs. For mir-146a rs2910164, 19 new studies were added; for mir-196a rs11614913, 11 new studies were added; for mir-499 rs3746444, 6 new studies were added; and for mir-149 rs2292832, 5 new studies were added. In addition, we analyzed 9 case-control studies on miR-27a rs895919, which were not included in the meta-analysis by He *et al*. [@pone.0079584-He1]. Thus, to the best of our knowledge, the present study is the most comprehensive and robust meta-analysis when compared to previously published meta-analyses in this field [@pone.0079584-Xu1], [@pone.0079584-Wang3]--[@pone.0079584-Xu5].

The rs2910164 (miR-146a) locus resides at position +60 relative to the first nucleotide of the pre-miR-146a gene. This polymorphism presents as a change from G to C in the passenger strand, resulting in a change from the G:U pair to the C:U mismatch in the stem structure of the miR-146a precursor [@pone.0079584-Akkiz2]. The C-allelic miR-146a precursor has lower transcriptional activity than the G-allele due to decreased nuclear primiR-146a processing efficiency; this leads to low levels of mature miR-146a and affects target mRNA binding [@pone.0079584-Xu3], [@pone.0079584-Jazdzewski1]. The decreased amount of miR-146a reduces the inhibition of target genes involved in the Toll-like receptor and cytokine signaling pathway (TRAF6, IRAK1) and impaired nuclear factor (NF)-κB activity [@pone.0079584-Jazdzewski1], [@pone.0079584-Bhaumik1]. Studies have shown that miR-146a plays an important role in cell proliferation and metastatic ability in some cancers and that its deregulation is possibly involved in carcinogenesis [@pone.0079584-Xu3], [@pone.0079584-Jazdzewski1], [@pone.0079584-Bhaumik1]--[@pone.0079584-LagosQuintana1]. However, the meta-analysis results suggested no significant association between this polymorphism and cancer susceptibility in the overall pooled result. In the case of subgroup analysis divided by cancer type, the rs2910164 C allele was associated with a decreased risk of bladder cancer, cervical cancer, colorectal cancer and prostate cancer, but an increased risk of PTC and SCCHN. In contrast to the previously published results by He *et al*. [@pone.0079584-He1], no significant association was found between rs2910164 and HCC or ESCC. These results suggest that the association between the miR-146a rs2910164 polymorphism and cancer susceptibility was cancer-type dependent. The potential explanation for this phenomenon may be that different cancers have differing pathogenesis. In addition, we found that the association between the rs2910164 polymorphism and cancer risk was ethnicity dependent, as supported by Wang *et al.* [@pone.0079584-Wang3]. This may be due to the difference in genetic backgrounds among races due to allele frequency or various carcinogenic mechanisms at tumor sites; another possibility may be that the polymorphism may be in linkage disequilibrium with the causal variant [@pone.0079584-Hirschhorn1]. In contrast to our results, He *et* *al*. [@pone.0079584-He1] found no association between this polymorphism and cancer risk among Caucasians.

MiR-196a2 is composed of two different mature miRNAs (miR-196a-5P and miR-196a-3P), which are processed from the same stem-loop [@pone.0079584-Chen4]. rs11614913, located in the mature sequence of miR-196a-3P, could influence the production levels of mature miR-196a and could have an impact on the expression of its target gene. Therefore, the altered expression patterns of miR-196a could influence its potential targets, which may play a role in regulating carcinogenesis. Previous meta-analysis studies have suggested an association between rs11614913 and the risk of cancers [@pone.0079584-Xu1], [@pone.0079584-Chu2]--[@pone.0079584-Wang4], [@pone.0079584-He1]--[@pone.0079584-Srivastava2]. The present meta-analysis also provides evidence that the miR-196a2 rs11614913 T allele is significantly associated with reduced cancer risk in the allelic contrast, the homozygote comparison, and the recessive models, similar to the findings of previous studies [@pone.0079584-He1]--[@pone.0079584-Srivastava2]. In the subgroup analysis that was divided by cancer type, homozygote TT had the effect of decreasing the risk of lung cancer and colorectal cancer compared with that for CC homozygote or C allele carriers. T allele carriers also showed decreased cancer susceptibility compared with homozygote CC carriers in liver cancer, whereas Wang *et al.* [@pone.0079584-Wang13] and He *et al*. [@pone.0079584-He1] reported that this polymorphism has no association with the risk of HCC. Moreover, no association was found between miR-196a2 rs11614913 and bladder cancer, breast cancer, gastric cancer, ESCC, or SCCHN. Guo *et al.* [@pone.0079584-Guo2] and Wang *et al.* [@pone.0079584-Wang5] found that the C allele could increase cancer risk in gastric cancer. In ethnic subgroup analysis, a strong association was found between rs11614913 and cancer risk among Asians but not among Caucasians, which was similar to the findings of previous studies [@pone.0079584-He1]--[@pone.0079584-Wang14]. In addition, biochemical studies on rs11614913 confirmed the results of our meta-analysis. It has been well established that Hox gene expression is deregulated in lung and prostate cancers [@pone.0079584-Miller1]--[@pone.0079584-Calvo1], and members of the Hox family have been found to be significantly downregulated in cells treated with pre-miR-196a-C [@pone.0079584-Calvo1]. Two tumor suppressors (GADD45G and INHBB) were reported to be downregulated and several oncogenes (TP63 and genes encoding two calcium-binding proteins) were found to be upregulated in breast cancer cells after pre-miR-196a-C introduction, suggestive of the oncogenic activity of pre-miR-196a-C and protective role of pre-miR-196a-T [@pone.0079584-Hoffman1], [@pone.0079584-Ying1]. Our results provide compelling evidence that the miR-196a2 rs11614913 polymorphism plays a crucial role in the development of cancer. Screening patients harboring the miR-196a2 rs11614913 polymorphism may prove clinically useful for the prediction and prevention of cancer.

The miR-499T\>C (rs3746444) polymorphism has been identified within the stem region of the mir-499 gene and results in an A:U to G:U mismatch in the stem structure of the miR-499 precursor. The presence of this mismatch would affect Sox6 and Rod1 genes, which are important for the etiology of cancers [@pone.0079584-Qi1], [@pone.0079584-Tano1]. Several studies have identified miR-499 rs3746444 as a possible biomarker for multiple cancers [@pone.0079584-Okubo1], [@pone.0079584-Catucci2], [@pone.0079584-Liu1], [@pone.0079584-Srivastava1], [@pone.0079584-Tian1]; however, the mechanism by which this occurs remains unknown. Our results showed that the rs3746444 C allele could increase cancer risk in the allelic contrast model and in the dominant model, which was consistent with the results of Srivastava *et al.* [@pone.0079584-Srivastava2]. In analysis stratified by cancer type, significant associations between the rs3746444 polymorphism and cancer risk were observed for breast cancer, which is in contrast to the results reported by Srivastava *et al*. [@pone.0079584-Srivastava2] and He *et al*. [@pone.0079584-He1]. However, no significant result was observed for other cancers under any genetic model. Subgroup analysis by ethnicity showed that the C allele was associated with increased cancer risk in the Asian population, but not in the Caucasian population.

For mir-149 rs2292832, a significant association was found only in some of the subgroup analyses but not in the pooled results. rs2292932 in miR-149 has been tested for several cancers but was not found to be associated with cancer risk [@pone.0079584-Vinci2], [@pone.0079584-Liu1], [@pone.0079584-Hu1], [@pone.0079584-Tian1], [@pone.0079584-Zhang4], [@pone.0079584-He1], [@pone.0079584-Srivastava2]. This suggests that the molecular mechanisms underlying the genetic associations of miRNA-SNPs with cancer risk may be complex and variable. Our results should be interpreted with caution, considering that the influence of the T allele in miR-149 might be masked by the presence of other unidentified causal genes involved in cancer development [@pone.0079584-Zhang4] and the limited number (12) of studies on this polymorphism. More studies will need to be analyzed to confirm the results.

MiR-27a rs895919 is located in the terminal loop of pre-miRNA-27a (an intergenic region of chromosome 19), which is upregulated in many tumors [@pone.0079584-Ma3] and has been considered to be an oncomir [@pone.0079584-Liu2]--[@pone.0079584-Wang15]. To date, several epidemiologic studies have been conducted to investigate the association between the rs895919 polymorphism and cancer risk [@pone.0079584-Shi1]--[@pone.0079584-Catucci1], [@pone.0079584-Sun1], [@pone.0079584-Yang1]; however, the results remain inconsistent and inconclusive. The results of two previous meta-analyses have indicated that the G allele in miR-27a rs895819 may be associated with decreased risk for some cancers, as well as with reduced cancer risk in Caucasians to some extent [@pone.0079584-Zhong1], [@pone.0079584-Xu4]. Based on our study, no association was observed between this polymorphism and cancer risk when all the data were pooled in the meta-analysis. Our results also showed that the rs895819 G allele was associated with decreased cancer risk in a Caucasian population, but was inconsistent with the abovementioned two articles on cancer type. Because of the limited number (9) of studies on this polymorphism, the results should be interpreted with caution.

Nevertheless, our study still has some limitations. First, relatively large heterogeneity was observed across some studies, which could be due to the difference in cancer types, the geographic areas (environmental factors), and genetic backgrounds of the samples. Second, the relatively small sample size of studies for some SNPs may lead to low statistical power, especially in stratified analysis. Third, lack of original data from the reviewed studies restricted further evaluation of potential interactions; this is of particular importance because gene--gene and gene--environment interactions may modulate various disease risks. Fourth, our analysis was limited to Asian and Caucasian ethnicities; therefore, it is uncertain whether these results can be generalized to other populations. Fifth, restriction to studies published in English or Chinese might confer potential language bias; moreover, publication bias might also exist because only published studies were included in this meta-analysis, and studies with no statistically significant results often have less chance for publication.

In conclusion, our results suggest that the miR-146a rs2910164 C allele is a protective factor for bladder cancer, prostate cancer, cervical cancer, and colorectal cancer in Asians, whereas it is a risk factor for PTC and SCCHN in Caucasians. mir-196a2 rs11614913 has significant association with overall cancer risk, especially for lung cancer, colorectal cancer, and other cancers in the Asian population. We also found that the mir-499 rs3746444 polymorphism could increase cancer risk in the Asian population. However, no significant association was observed between mir-149 rs2292832 and miR-27a rs895919 and overall cancer risk. Further studies with a larger sample size will be needed to clarify the possible roles of these polymorphisms in different kinds of cancers.

Supporting Information {#s5}
======================

###### 

**Begg's funnel plot of publication bias for miR-146a rs2910164 G\>C: C vs. G.** Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.

(TIF)

###### 

Click here for additional data file.

###### 

**Begg's funnel plot of publication bias for miR-196a2 rs11614913 C\>T: T vs. C.** Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.

(TIF)

###### 

Click here for additional data file.

###### 

**Begg's funnel plot of publication bias for miR-499 rs3746444 T\>C: C vs. T.** Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.

(TIF)

###### 

Click here for additional data file.

###### 

**Begg's funnel plot of publication bias for miR-149 rs2292832 C\>T: T vs. C.** Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.

(TIF)

###### 

Click here for additional data file.

###### 

**Begg's funnel plot of publication bias for miR-27a rs895919A\>G: G vs. A.** Each point represents a separate study for the indicated association. Log\[or\], natural logarithm of OR. Horizontal line, mean effect size.

(TIF)

###### 

Click here for additional data file.
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